

1 **Classification:**

2 Biological Sciences, Biophysics and Computational Biology

3 **Modelling SARS-CoV-2 Dynamics: Implications** 4 **for Therapy**

5 Kwang Su Kim^a, Keisuke Ejima^b, Yusuke Ito^a, Shoya Iwanami^a, Hirofumi Ohashi^c,
6 Yoshiki Koizumi^d, Yusuke Asai^d, Shinji Nakaoka^{e,f}, Koichi Watashi^{c,g,h,i,j}, Robin N.
7 Thompson^{k,l,1}, and Shingo Iwami^{ja,h,i,m,1}

8
9 ^aDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan
10 8190395. ^bDepartment of Epidemiology and Biostatistics, Indiana University School
11 of Public Health-Bloomington, IN, USA 47405. ^cDepartment of Virology II, National
12 Institute of Infectious Diseases, Tokyo, Japan 1628640. ^dNational Center for Global
13 Health and Medicine, Tokyo, Japan 1628655. ^eFaculty of Advanced Life Science,
14 Hokkaido University, Sapporo, Japan 060-0808. ^fPRESTO, JST, Saitama, Japan
15 3320012. ^gDepartment of Applied Biological Science, Tokyo University of Science,
16 Noda, Japan 2788510. ^hMIRAI, JST, Saitama, Japan 3320012. ⁱCREST, JST,
17 Saitama, Japan 3320012. ^jInstitute for Frontier Life and Medical Sciences, Kyoto
18 University, Kyoto, Japan 6068507. ^kChrist Church, University of Oxford, Oxford OX1
19 1DP, UK. ^lMathematical Institute, University of Oxford, Oxford OX2 6GG, UK,
20 Fukuoka, UK. ^mScience Groove Inc., Fukuoka, Japan 8100041.

21

22 ¹To whom correspondence may be addressed.

23 Email: robin.thompson@chch.ox.ac.uk (R.N.T.) and siwami@kyushu-u.org (S.I.).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract (230/250)**

25 The scientific community is focussed on developing antiviral therapies to
26 mitigate the impacts of the ongoing novel coronavirus disease (COVID-19) outbreak.
27 This will be facilitated by improved understanding of viral dynamics within infected
28 hosts. Here, using a mathematical model in combination with published viral load
29 data collected from the same specimen (throat / nasal swabs or nasopharyngeal /
30 sputum / tracheal aspirate), we compare within-host dynamics for patients infected in
31 the current outbreak with analogous dynamics for MERS-CoV and SARS-CoV
32 infections. Our quantitative analyses revealed that SARS-CoV-2 infection dynamics
33 are more severe than those for mild cases of MERS-CoV, but are similar to severe
34 cases, and that the viral dynamics of SARS-CoV infection are similar to those of
35 MERS-CoV in mild cases but not in severe case. Consequently, SARS-CoV-2
36 generates infection dynamics that are more severe than SARS-CoV. Furthermore,
37 we used our viral dynamics model to predict the effectiveness of unlicensed drugs
38 that have different methods of action. The effectiveness was measured by AUC of
39 viral load. Our results indicated that therapies that block *de novo* infections or virus
40 production are most likely to be effective if initiated before the peak viral load (which
41 occurs around three days after symptom onset on average), but therapies that
42 promote cytotoxicity are likely to have only limited effects. Our unique mathematical
43 approach provides insights into the pathogenesis of SARS-CoV-2 in humans, which
44 are useful for development of antiviral therapies.

45 **Keywords:**

46 SARS-CoV-2, MERS-CoV, SARS-CoV, mathematical model, antiviral therapy

47 **Significance Statement (80/120)**

48 Antiviral agents with different mechanisms of action have different curative effects
49 depending on precisely when therapy is initiated. Based on a model of viral
50 dynamics, parameterised using viral load data from SARS-CoV-2 infected patients
51 reported by Zou *et al.* (1), computer simulations were performed. We propose that
52 effective treatment of SARS-CoV-2 infection requires an appropriate choice of class-
53 specific drugs and initiation timing as reported for treatment of other viral infections
54 (2); otherwise, antivirals do not have a significant effect on the within-host viral
55 dynamics of SARS-CoV-2 and are wasted.

56 \body

57 **Text**

58 The ongoing coronavirus disease 2019 (COVID-19) outbreak was first
59 reported in Wuhan, China in late December 2019 (3, 4). Since then, the causative
60 agent (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has been
61 transmitted elsewhere in China and to 80 other countries and territories around the
62 world. The number of confirmed cases currently stands at 139,061 (as of 13 March
63 2020). The possibility of presymptomatic or asymptomatic cases (5), combined with
64 underreporting of symptomatic infections, suggests that the true number of cases is
65 likely to be even higher than this.

66 Antiviral drugs (for treatment and to avoid onwards transmission) and a
67 vaccine (for prevention) are currently under development to counter this outbreak. To
68 aid the development process, characterisation of the viral dynamics of SARS-CoV-2
69 both *in vivo* and *in vitro* is crucial. The virus has been isolated, genome sequencing
70 has been completed and the resulting data were made publicly available early in the
71 outbreak (6, 7). Furthermore, the viral load in upper respiratory specimens (throat
72 and nasal swabs) of infected patients over 20 days after symptom onset has been
73 reported (2). However, the viral dynamics of SARS-CoV-2 infections have not been
74 studied quantitatively, and the data have not been compared with analogous
75 datasets for other coronaviruses. Such quantitative analyses are informative for the
76 development of antiviral agents, addressing questions such as the optimal viral-host
77 processes for antiviral drugs or vaccines to target.

78 Results and Discussion

79 Characterising SARS-CoV-2 and MERS-CoV infections by analysing viral load 80 measurements collected from throat swabs

81 We analysed data describing SARS-CoV-2 viral loads reported by Zou *et al.*
82 (1) and MERS-CoV viral loads reported by Oh *et al.* (8) using a simple mathematical
83 model (see **Methods**). To consider inter-individual variations in viral loads, a
84 nonlinear mixed-effect modelling approach was employed to estimate parameters
85 (see **Methods**). The estimated parameters and initial values are listed in **Table 1**,
86 and the typical behaviour of the model using these best-fit parameter estimates is
87 shown together with the data in **Fig. 1A** for SARS-CoV-2 (pink) and MERS-CoV
88 (black and grey for severe and mild case, respectively). In addition, to parameterise
89 and compare these coronaviruses infections, we calculated the following important
90 quantities (**Fig. 2**) using estimated parameter values; the mean length of virus
91 production of an infected cell ($L = 1/\delta$), the within-host basic reproduction number
92 ($R_0 = \gamma/\delta$) which is the average number of newly infected cells produced by any
93 single infected cell (9), and the critical inhibition rate ($C^* = 1 - 1/R_0$) induced by
94 antivirals to prevent primary virus infection (10, 11). We showed that L is not
95 significantly different for SARS-CoV-2 and MERS-CoV. However, interestingly, we
96 found that R_0 and C^* for SARS-CoV-2 are significantly different from analogous
97 values for mild cases of MERS-CoV ($p = 8.9 \times 10^{-4}$ and 2.0×10^{-6} by the bootstrap
98 t -test, respectively), but not for severe MERS-CoV ($p = 0.41$ and 0.41) (see **Fig. 2**),
99 although we were unable to separate mild and severe cases of SARS-CoV-2 due to
100 limited clinical information for the cases. This demonstrates that SARS-CoV-2
101 causes infection more effectively than in mild cases of MERS-CoV, but a general
102 SARS-CoV-2 infection follows infection dynamics that are similar to severe cases

103 due to MERS-CoV. In addition, as a median estimate, 65% inhibition of the initial
104 virus expansion is required to prevent the establishment of SARS-CoV-2 infection
105 (we provide a detailed analysis later). We also calculated the duration of infection in
106 which the viral load is above the detection limit (T_{VL}) in **Table 1**, showing that SARS-
107 CoV-2 is maintained in hosts for more than a week based on the median estimate.

108

109 **Characterising SARS-CoV and MERS-CoV infections by analysing viral load** 110 **measurements collected from nasopharyngeal/sputum/tracheal aspirate**

111 To extend our analysis to include SARS-CoV, we analysed SARS-CoV viral
112 loads in nasopharyngeal aspirate reported by Peiris *et al.* (12) and MERS-CoV viral
113 loads reported by Oh *et al.* (8) in sputum or tracheal aspirate. The estimated
114 parameters, viral load at symptom onset, and the indices derived from the estimated
115 parameters are listed in **Table 1** and **Fig. 2**, and the typical behaviour of the model is
116 shown together with the data in **Fig. 1B** for SARS-CoV (blue) and MERS-CoV (black
117 or grey). The estimated values of L for SARS-CoV and MERS-CoV are not
118 significantly different. Surprisingly, the estimated values of R_0 and C^* for SARS-CoV
119 are significantly different from those for severe cases of MERS-CoV ($p = 0.03$ and
120 0.02 from bootstrap t -test), but not for mild MERS-CoV cases ($p = 0.52$ and 0.47
121 from bootstrap t -test) (**Fig. 2**). This demonstrates that *in vivo* viral dynamics of
122 SARS-CoV infection are similar to those for MERS-CoV in mild cases but not in
123 severe cases. Collectively, the findings from the viral load data analyses for the two
124 different specimens (throat/nasal swabs and nasopharyngeal/sputum/tracheal
125 aspirate) implied that SARS-CoV-2 also causes infection more effectively than
126 SARS-CoV.

127

128 **Evaluation of anti-SARS-CoV-2 therapies**

129 Our quantitative analyses provide insights into optimal usage of anti-SARS-
130 CoV-2 therapies under development. In particular, it remains poorly understood how
131 a delay of treatment initiation after primary infection, or how incomplete blocking of
132 virus infection/replication, impacts the viral load dynamics. Based on our
133 mathematical model and estimated parameter values (**Table 1**), we conducted *in*
134 *silico* experiments for possible anti-SARS-CoV-2 therapies to investigate the
135 expected outcome under hypothetical drug therapies (or vaccine use) possessing
136 different antiviral mechanisms (**Fig. 3**).

137

138 **(i) Blocking *de novo* infection**

139 One of the major mechanisms of action for antivirals is blocking *de novo*
140 infections. This can be induced by drugs including human neutralising antibodies,
141 viral entry-inhibitors and/or antibodies raised by vaccination (13, 14). For example, a
142 SARS-CoV-specific human monoclonal antibody has been reported to cross react
143 with SARS-CoV-2 (14). We conducted *in silico* experiments with varying drug
144 efficacy (considering inhibition rates from 10% to 100%, i.e. $0.1 \leq \varepsilon \leq 1$) and with the
145 timing of initiation of therapy from 0 days (i.e., post-exposure prophylactic use of
146 antivirals) until 5 days after symptom onset (i.e., $0 \leq t^* \leq 5$) (see **Methods**). Our
147 results show that early initiation of therapy (especially within two to three days) with
148 even a relatively weak drug (inhibition rates as low as 50%) might effectively reduce
149 the area under the curve of viral load (AUC) and prevent significant reductions in the
150 numbers of target cells because of cytopathic effects due to cell invasion. A therapy
151 of this type initiated four days after symptom onset, on the other hand, is not
152 predicted to induce a clear antiviral effect (**Fig. 3AD**). This suggests that blocking *de*

153 *novo* infections is not likely to be effective unless the intervention is initiated before
154 the peak viral load. Hence, appropriate initiation timing (i.e., before or very soon after
155 symptom onset) is an important factor for suppressing viral load in addition to the
156 therapy having the potential for antiviral effects.

157

158 **(ii) Blocking virus production**

159 The majority of antiviral drugs inhibit intracellular virus replication. Although
160 their antiviral efficacies need to be confirmed, lopinavir/ritonavir (HIV protease
161 inhibitors), remdesivir (anti-Ebola virus disease candidate) and other nucleoside
162 analogues, and interferon have the potential to suppress SARS-CoV-2 by blocking
163 virus production(15, 16). Interestingly, our results suggest that, even for relatively
164 small inhibition rates of around 30%, the AUC of viral load is partially reduced if
165 therapy is initiated early (within three days after symptom onset) (**Fig. 3BE**).
166 However, if treatment is applied after the peak viral load, even drugs with 100%
167 inhibition rate are not able to reduce viral loads, which is similar to the predicted
168 outcomes of *de novo* blocking therapy.

169

170 **(iii) Promoting cytotoxicity**

171 Another possible antiviral mechanism is cytotoxic effects by adaptive
172 immunity including those mediated by cytotoxic T lymphocytes. Here, we assume
173 that promoting cytotoxicity increases the virus death rate by at most two times (i.e.,
174 $0.1 \leq \theta \leq 1$), that is, achieves up to 50% reduction of the mean length of virus
175 production. Compared with the other two therapies (blocking *de novo* infection and
176 virus production), the induction of cytotoxicity had relatively mild effects on the AUC
177 reduction if initiated before peak viral load. However, cytotoxicity induction initiated

178 after peak viral load could effectively reduce the viral load AUC (**Fig. 3CF**). This
179 implies that there is an optimal time to apply this therapy, and that significant antiviral
180 effects are expected unless the promoting rate is too low or therapy is initiated either
181 too early or too late. However, large reductions of target cells due to ongoing *de*
182 *novo* infection cannot be avoided even with very early initiation (i.e., immediately
183 after symptom onset) of the therapy.

184 **Conclusions**

185 There are a number of potential transmission routes of SARS-CoV-2,
186 including direct person-to-person transmission due to viral particle inhalation and
187 contact transmission due to contact with nasal/oral/eye mucuous membranes. The
188 risk of transmission depends on the viral load of the potential infector. Consequently,
189 treatments reducing the viral load are important for the prevention of secondary
190 transmission and aid population-scale outbreak control. We characterised viral
191 infection dynamics using a mathematical model, and assessed potential strategies to
192 reduce viral loads. Our analyses showed that both blocking *de novo* infection and
193 virus production effectively reduces AUC of SARS-CoV-2 load; for example, if the
194 therapy can reduce more than 90% of *de novo* infections and is initiated 3 days after
195 symptoms onset, the viral load AUC is expected to be reduced by 81.4% (**Fig. 3DE**).
196 However, if therapy is initiated after peak viral load (more than 2-3 days following
197 symptom onset), the effect on viral load AUC is limited. Compared with either
198 blocking *de novo* infection or virus production, promoting cytotoxicity showed
199 relatively mild effects on AUC reduction, however initiation of that therapy after the
200 peak viral load has the potential to still reduce viral load AUC (**Fig. 3F**).

201 The effectiveness of the hypothetical drugs can be evaluated in detail using a
202 cell culture system supporting SARS-CoV-2 infection (13). Wang *et al.* proposed
203 different classes of drugs for treating SARS-CoV-2 infections: chloroquine inhibited
204 viral entry and remdesivir suppressed the virus post-entry, likely by suppressing viral
205 replication (13). Although animal models for testing treatments have not been
206 reported for SARS-CoV-2, a number of animal models exist for SARS-CoV including
207 mice, hamsters, ferrets, and macaques (17). Animals could be used to verify the
208 conclusions from our models, by monitoring the viral loads in animals treated with

209 different types of drugs at different doses and different initiation timings. Such viral
210 load data would allow further investigation of the effectiveness of drugs with different
211 action mechanisms, which would be informative for development of appropriate
212 treatment strategies (i.e., the optimal dose/timing of antivirals) for SARS-CoV-2
213 infections.

214 In conclusion, effective treatment of SARS-CoV-2 infections requires an
215 appropriate choice of class-specific drugs; otherwise, the antivirals do not alter the
216 viral load significantly and are wasted. Identification of SARS-CoV-2-specific virus
217 characteristics is needed to design optimal treatments and to ensure that limited
218 resources are deployed effectively. Additionally, effective combinations of anti-
219 SARS-CoV-2 drugs and vaccines will maximise the impacts of control, reduce the
220 required drug dose and potentially limit side effects, all of which are highly desirable.
221 Our theoretical approach could complement ongoing experimental investigations into
222 SARS-CoV-2 infection in BSL-3 laboratories and help establish a basis for COVID-
223 19 treatment. To our knowledge, previous studies have neither characterised SARS-
224 CoV-2 dynamics in humans using viral dynamics models, nor compared the resulting
225 dynamics against those of other coronaviruses (i.e., SARS-CoV and MERS-CoV).
226 Our mathematical modelling approach has led to an improved understanding of the
227 characteristics of SARS-CoV-2 *in vivo*, and can be used to test possible treatments
228 for COVID-19 further going forwards.

229 **Methods**

230 **Study data**

231 The data examined in our manuscript came from studies of SARS-CoV-2,
232 MERS-CoV and SARS-CoV by Zou *et al.* (1), Oh *et al.* (8) and Peiris *et al.* (12),
233 respectively. To extract the data from images in those publications, we used the
234 program datathief III (version 1.5, Bas Tummers, www.datathief.org). We excluded
235 patients for whom data were measured on only one day, and assumed that viral load
236 values under the detection limit were set as the detection limit for the purposes of
237 fitting the model. We converted cycle threshold (Ct) values reported in Zou *et al.* (1),
238 Oh *et al.* (8) and Peiris *et al.* (12) to viral RNA copies number values, where these
239 quantities are inversely proportional to each other (18).

240

241 **Mathematical model**

242 To parameterise coronavirus infection dynamics from patient viral load data,
243 we derived a simplified mathematical model from the following virus dynamics
244 model:

$$245 \quad \frac{dT(t)}{dt} = -\beta T(t)V(t), \quad (1)$$

$$246 \quad \frac{dI(t)}{dt} = \beta T(t)V(t) - \delta I(t), \quad (2)$$

$$247 \quad \frac{dV(t)}{dt} = pI(t) - cV(t), \quad (3)$$

248 where the variables $T(t)$, $I(t)$ and $V(t)$ are the numbers of uninfected target cells,
249 infected target cells, and the amount of virus at time t , respectively. The parameters
250 β , δ , p , and c represent the rate constant for virus infection, the death rate of infected
251 cells, the viral production rate, and the clearance rate of the virus, respectively. Since

252 the clearance rate of virus is typically much larger than the death rate of the infected
253 cells *in vivo* (10, 19, 20), we made a quasi-steady state (QSS) assumption,
254 $dV(t)/dt = 0$, and replaced Eq.(3) with $V(t) = pI(t)/c$. Because data on the
255 numbers of coronavirus RNA copies, $V(t)$, rather than the number of infected cells,
256 $I(t)$, were available, then $I(t) = cV(t)/p$ was substituted into Eq.(2) to obtain

257
$$\frac{dV(t)}{dt} = \frac{p\beta}{c}T(t)V(t) - \delta V(t). \quad (4)$$

258 Furthermore, we defined the ratio of the number of uninfected target cells at time t to
259 the initial number of uninfected target cells $T(0)$, that is, $f(t) = T(t)/T(0)$.
260 Accordingly, we obtained the following simplified mathematical model, which we
261 employed to analyse the data in this study:

262
$$\frac{df(t)}{dt} = -\beta f(t)V(t), \quad (5)$$

263
$$\frac{dV(t)}{dt} = \gamma f(t)V(t) - \delta V(t), \quad (6)$$

264 where $\gamma = p\beta T(0)/c$ is defined as the maximum viral replication rate for coronavirus
265 infections. Note that the ratio $f(t)$ is always less than or equal to 1.

266 In our analyses, the variable $V(t)$ corresponds to the viral load in throat swabs
267 for SARS-CoV-2 and MERS-CoV and in nasopharyngeal/sputum/tracheal aspirate
268 for SARS-CoV and MERS-CoV. In the case of acute coronavirus infection, the loss
269 of target cells by physiological turnover could be ignored, considering the long life-
270 span of the target cells. Patient viral load data for SARS-CoV-2/SARS-CoV/MERS-
271 CoV were fitted using a nonlinear mixed-effect modelling approach (described
272 below), which uses the whole sample to estimate population parameters but also
273 account for inter-individual variation.

274

275 ***In silico* experiments for possible anti-SARS-CoV-2 therapies**

276 By utilising our novel mathematical model and the estimated parameter
277 values, we investigated the antiviral effects of unlicensed but developing (promising)
278 drugs with the following different mechanisms of action, depending on inhibition rates
279 and timings of therapy initiation: (i) blocking *de novo* infection (e.g. via human
280 neutralising antibodies, viral entry-inhibitors and antibody levels raised by
281 vaccination (13, 14)); (ii) blocking virus production (such as lopinavir/ritonavir (HIV
282 protease inhibitors), remdesivir (an anti-Ebola virus candidate) and other nucleoside
283 analogues, and interferon (15, 16)); and (iii) promoting cytotoxicity (by adaptive
284 immunity such as cytotoxic T lymphocytes). To simulate possible variations in the
285 viral load and in the target cell numbers under these different types of anti-SARS-
286 CoV-2 therapy, the median parameter sets were used to predict the expected
287 outcome of each therapy. In other words, even though no drug administration trials
288 have been conducted yet, we were able to infer the efficacy of each drug treatment
289 based on our *in silico* experiments. We implemented the different mechanisms of
290 action in the model as follows:

291 (i) Blocking *de novo* infection. The antiviral effect of blocking *de novo* infection
292 therapy ($0 < \varepsilon \leq 1$. $\varepsilon = 1$ implies *de novo* infection is 100% inhibited) initiated at t^*
293 days after symptom onset was modelled by assuming:

$$294 \quad \frac{df(t)}{dt} = -(1 - \varepsilon \times H(t))\beta f(t)V(t), \quad (7)$$

$$295 \quad \frac{dV(t)}{dt} = (1 - \varepsilon \times H(t))\gamma f(t)V(t) - \delta V(t), \quad (8)$$

296 where $H(t)$ is a Heaviside step function defined as $H(t) = 0$ if $t < t^*$: otherwise
297 $H(t) = 1$. We evaluated the expected antiviral effect of the therapy under different
298 inhibition rates (ε) and initiation timings (t^*) using our estimated parameter values.

299 The mean reduction of cumulative virus production, i.e., the area under the curve of
300 viral load (AUC: $\int_0^{28} V(s)ds$: because the observed durations COVID-19 infection are
301 longer than previous coronavirus infection (i.e., SARS-CoV and MERS-CoV), we
302 used the maximum length of observations 28 days as the upper bound for
303 integration), induced by blocking *de novo* infection for SARS-CoV-2 was calculated.
304 Note that the expected values at day 0 after symptom onset ($t^* = 0$) corresponds to
305 the antiviral effect of therapy initiated immediately after symptom onset.

306 (ii) Blocking virus production. Alternatively, we assumed an inhibition rate of
307 virus production of $0 < \eta \leq 1$. The antiviral effect by blocking virus production ($0 <$
308 $\eta \leq 1$. $\eta = 1$ indicates that the virus reproduction from the infected cells are perfectly
309 inhibited) is modelled as follows:

$$310 \quad \frac{dV(t)}{dt} = (1 - \eta \times H(t))\gamma f(t)V(t) - \delta V(t). \quad (9)$$

311 Note that the difference between blocking *de novo* infection and virus production is
312 that the former reduces β , whereas the latter reduces p in the full model (1)-(3).

313 (iii) Promoting cytotoxicity. The antiviral effect of promoting cytotoxicity
314 therapy ($0 < \theta \leq 1$. $\theta = 1$ indicates that the mean duration of virus production is
315 doubled) was modelled as follows:

$$316 \quad \frac{dV(t)}{dt} = \gamma f(t)V(t) - (1 + \theta \times H(t))\delta V(t). \quad (10)$$

317

318 **The nonlinear mixed effect model**

319 MONOLIX 2019R2 (www.lixoft.com), a program that implements a maximum
320 likelihood estimation procedure for parameters in a nonlinear mixed-effects model,
321 was employed to fit to the viral load data. Nonlinear mixed-effects modelling
322 approaches allow a fixed effect as well as a random effect describing the inter-

323 patient variability. Including a random effect amounts to a partial pooling of the data
324 between individuals to improve estimates of the parameters applicable across the
325 population of patients. By using this approach, the differences between viral
326 dynamics in different patients were not estimated explicitly, nor did we fully pool the
327 data which would bias estimates towards highly sampled patients. In this method of
328 estimation, each parameter estimate $\vartheta_i (= \vartheta \times e^{\pi_i})$ depends on the individual where
329 ϑ is fixed effect, and π_i is random effect with an assumed Gaussian distribution with
330 mean 0 and standard deviation Ω . Population parameters and individual parameters
331 were estimated using the stochastic approximation expectation-maximisation
332 algorithm and empirical Bayes' method, respectively. Individual estimated
333 parameters and initial values for patients are summarized in **Table S1**. Using
334 estimated individual parameters and a Markov chain Monte Carlo algorithm, the
335 conditional distribution is obtained which can represent the uncertainty in individual
336 parameter values. We obtained 100 sets of estimated parameters for each individual
337 patient by fitting the simplified mathematical model (Eqs. (5-6)) to the data. The
338 estimation was performed for viral loads in throat swab from SARS-CoV-2, mild
339 MERS-CoV, and severe MERS-CoV separately, and the distributions of the
340 parameters were compared and tested using the bootstrap t -test. Due to the small
341 sample size for viral loads in sputum/tracheal aspirate for MERS-CoV, we assumed
342 the fixed effect was the same for mild and severe MERS-CoV cases. Otherwise, the
343 process was exactly the same as that described for the throat swab data.

344

345 **The computation of L , R_0 , C^* and T_{VL}**

346 Based on the estimated parameter distributions, we calculated several
347 quantities: the duration of virus production (L), the basic reproduction number (R_0),

348 and the critical inhibition rate (C^*). We also calculated the period during which the
349 viral load was above the detection limit (T_{VL}) from the *in silico* simulations with
350 individual estimated parameters and an initial viral load equal the detection limit (i.e.
351 numerical experiments began at the point at which the virus became detectable).
352 The distributional estimates of R_0 , L , C^* and T_{VL} were calculated separately for
353 SARS-CoV-2 and SARS-CoV, as well as for severe and mild cases of MERS-CoV.

354 **Acknowledgments**

355 This study was supported in part by Basic Science Research Program
356 through the National Research Foundation of Korea funded by the Ministry of
357 Education 2019R1A6A3A12031316 (to K.S.K.); Grants-in-Aid for JSPS Scientific
358 Research (KAKENHI) Scientific Research B 17H04085 (to K.W.), 18KT0018 (to S.I.),
359 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research S 15H05707 (to S.N.),
360 Scientific Research in Innovative Areas 19H04839 (to S.I.), 18H05103 (to S.I.);
361 AMED CREST 19gm1310002 (to S.I.); AMED J-PRIDE 19fm0208019j0003 (to K.W.),
362 19fm0208006s0103 (to S.I.), 19fm0208014h0003 (to S.I.), 19fm0208019h0103 (to
363 S.I.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.I.); Research
364 Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to
365 S.I.); Program for Basic and Clinical Research on Hepatitis 19fk0210036j0002 (to
366 K.W.), 19fk0210036h0502 (to S.I.); Program on the Innovative Development and the
367 Application of New Drugs for Hepatitis B 19fk0310114j0003 (to K.W.),
368 19fk0310101j1003 (to K.W.) , 19fk0310103j0203 (to K.W.), 19fk0310114h0103 (to
369 S.I.); JST PRESTO (to S.N.); JST MIRAI (to K.W. and S.I.); JST CREST (to K.W.
370 and S.I.); The Yasuda Medical Foundation (to K.W.); Smoking Research Foundation
371 (to K.W.); Takeda Science Foundation (to K.W.); Mochida Memorial Foundation for
372 Medical and Pharmaceutical Research (to K.W.); Mitsui Life Social Welfare
373 Foundation (to S.I. and K.W.); Shin-Nihon of Advanced Medical Research (to S.I.);
374 Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.);
375 SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation
376 (to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); Fukuoka
377 Financial Group, Inc. (to S.I.); Kyusyu Industrial Advancement Center Gapfund

378 Program (to S.I.); Foundation for the Fusion Of Science and Technology (to S.I.); a
379 Junior Research Fellowship from Christ Church, Oxford (to R.N.T.)

380

381 **Competing interests**

382 The authors declare that they have no competing interests.

383

384 **Authors' contributions**

385 Conceived and designed the study: KE KW RNT SI. Analysed the data: KSK

386 KE YI SI HO YK SN SI. Wrote the paper: KSK KE KW RNT SI. All authors read and

387 approved the final manuscript.

388 References

- 389 1. Zou L, *et al.* (2020) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of
390 Infected Patients. *N Engl J Med*.
- 391 2. Fry AM, *et al.* (2014) Efficacy of oseltamivir treatment started within 5 days of
392 symptom onset to reduce influenza illness duration and virus shedding in an urban
393 setting in Bangladesh: a randomised placebo-controlled trial. *Lancet Infect Dis*
394 14(2):109-118.
- 395 3. Li Q, *et al.* (2020) Early Transmission Dynamics in Wuhan, China, of Novel
396 Coronavirus-Infected Pneumonia. *N Engl J Med*.
- 397 4. Thompson RN (2020) Novel Coronavirus Outbreak in Wuhan, China, 2020: Intense
398 Surveillance Is Vital for Preventing Sustained Transmission in New Locations. *J Clin*
399 *Med* 9(2).
- 400 5. Chan JF, *et al.* (2020) A familial cluster of pneumonia associated with the 2019 novel
401 coronavirus indicating person-to-person transmission: a study of a family cluster.
402 *Lancet* 395(10223):514-523.
- 403 6. Zhu N, *et al.* (2020) A Novel Coronavirus from Patients with Pneumonia in China,
404 2019. *N Engl J Med* 382(8):727-733.
- 405 7. Lu R, *et al.* (2020) Genomic characterisation and epidemiology of 2019 novel
406 coronavirus: implications for virus origins and receptor binding. *Lancet*
407 395(10224):565-574.
- 408 8. Oh MD, *et al.* (2016) Viral Load Kinetics of MERS Coronavirus Infection. *N Engl J*
409 *Med* 375(13):1303-1305.
- 410 9. Perelson AS (2002) Modelling viral and immune system dynamics. *Nat Rev Immunol*
411 2(1):28-36.
- 412 10. Martyushev A, Nakaoka S, Sato K, Noda T, & Iwami S (2016) Modelling Ebola virus
413 dynamics: Implications for therapy. *Antiviral Res* 135:62-73.
- 414 11. Iwami S, *et al.* (2012) Identifying viral parameters from in vitro cell cultures. *Front*
415 *Microbiol* 3:319.
- 416 12. Peiris JS, *et al.* (2003) Clinical progression and viral load in a community outbreak of
417 coronavirus-associated SARS pneumonia: a prospective study. *Lancet*
418 361(9371):1767-1772.
- 419 13. Wang M, *et al.* (2020) Remdesivir and chloroquine effectively inhibit the recently
420 emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*.
- 421 14. Tian X, *et al.* (2020) Potent binding of 2019 novel coronavirus spike protein by a
422 SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes Infect*
423 9(1):382-385.
- 424 15. Yao TT, Qian JD, Zhu WY, Wang Y, & Wang GQ (2020) A Systematic Review of
425 Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible
426 Reference for Coronavirus Disease-19 Treatment Option. *J Med Virol*.
- 427 16. Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV).
428 *Biosci Trends*.
- 429 17. Peiris JS, Yuen KY, Osterhaus AD, & Stohr K (2003) The severe acute respiratory
430 syndrome. *N Engl J Med* 349(25):2431-2441.
- 431 18. Poon LL, *et al.* (2004) Detection of SARS coronavirus in patients with severe acute
432 respiratory syndrome by conventional and real-time quantitative reverse transcription-
433 PCR assays. *Clin Chem* 50(1):67-72.
- 434 19. Ikeda H, *et al.* (2016) Quantifying the effect of Vpu on the promotion of HIV-1
435 replication in the humanized mouse model. *Retrovirology* 13:23.
- 436 20. Nowak MA & May RM (2000) Virus dynamics. (Oxford University Press Oxford).

437 **Figure legends**

438 **Fig. 1.** Mathematical model outputs for individual patients based on fits to viral load
439 data for SARS-CoV-2, MERS-CoV and SARS-CoV. Viral loads were measured using
440 throat swabs for SARS-CoV-2 and MERS-CoV (**A**) and nasopharyngeal/sputum
441 swabs or tracheal aspirate for SARS-CoV and MERS-CoV (**B**) infected patients.
442 Severe and mild cases of MERS-CoV are shown in black and gray, respectively.
443 Note that the detection limits of measurements of SARS-CoV-2, MERS-CoV and
444 SARS-CoV viral loads are 14.6, 1000 and 1000 copies/ml, respectively.

445
446 **Fig. 2.** Characterisation and comparison of SARS-CoV-2, MERS-CoV and SARS-
447 CoV infection dynamics *in vivo*. Distribution of estimates for (**A**) the mean duration of
448 virus production of an infected cell, $L = 1/\delta$, (**B**) the within-host basic reproduction
449 number, $R_0 = \gamma/\delta$, and (**C**) the critical inhibition rate, $C^* = 1 - 1/R_0$. Estimates of R_0
450 and C^* for SARS-CoV-2 are significantly different compared to analogous estimates
451 for mild cases of MERS-CoV, but not compared to estimates for severe MERS-CoV.
452 On the other hand, estimates for SARS-CoV are significantly different from those for
453 severe cases of MERS-CoV but not for mild cases of MERS-CoV.

454
455 **Fig. 3.** *In silico* experiments to predict the outcomes of possible anti-SARS-CoV-2
456 therapies. In each case, the therapy was initiated after 2 (★) or 4 (●) days from
457 symptom onset with 90% inhibition rate. The expected dynamics of the viral loads
458 (top) and the uninfected target cell ratio (bottom) under the hypothetical therapy
459 (antiviral drug or vaccine) for blocking *de novo* infection, virus production, and
460 promoting cytotoxic effects are shown in (**A**), (**B**) and (**C**), respectively, using the
461 median values of our estimated parameters and an initial viral load that is equal to

462 the detection limit. The coloured solid curves and black dashed curves correspond to
463 SARS-CoV-2 infection dynamics with and without the therapies. In addition, we
464 simulated the model for a range of therapy efficacies and times at which therapies
465 were introduced, and the results are summarised in **(D)**, **(E)** and **(F)** for therapies that
466 block *de novo* infection, block virus production and promote cytotoxic effects,
467 respectively. Darker regions of these panels indicate a larger reduction in AUC of
468 viral load which implies a stronger antiviral effect against SARS-CoV-2 infection. The
469 expected values with $t^*=0$ indicate the antiviral effect of pre-exposure vaccines (or
470 post-exposure prophylactic use of antivirals).

Table 1. Estimated parameters for SARS-CoV-2 and MERS-CoV infection obtained from throat swabs

Parameter Name	Symbol (Unit)	SARS-CoV-2	MERS-CoV	
			Mild	Severe
Parameters obtained from fitting to the clinical time-series datasets				
Maximum rate constant for viral replication	γ (day ⁻¹)	4.55 [†]	3.36	3.76
Rate constant for virus infection	β ((copies/ml) ⁻¹ day ⁻¹)	6.77×10^{-5}	2.10×10^{-6}	1.10×10^{-6}
Death rate of infected cells	δ (day ⁻¹)	1.59	2.47	1.32
Viral load at symptom onset	$V(0)$ (copies/ml)	21.8	2.43×10^{-4}	1.21×10^{-3}
Quantities derived from estimated parameters				
Within-hots basic reproduction number	R_0	2.87	1.36	2.84
Critical inhibition rate	C^*	0.65	0.26	0.65
Length of virus production	L	0.63	0.41	0.76
Length of viral load above detection limit	T_{VL} (days)	9.34	10.9	14.0


[†] Median value

Table 2. Estimated parameters for SARS-CoV and MERS-CoV infection obtained from nasopharyngeal/sputum/tracheal aspirate


Parameter Name	Symbol (Unit)	SARS-CoV	MERS-CoV	
			Mild	Severe
Parameters obtained from fitting to the clinical time-series datasets				
Maximum rate constant for viral replication	γ (day ⁻¹)	3.09 [†]	3.14	3.10
Rate constant for virus infection	β ((copies/ml) ⁻¹ day ⁻¹)	8.24×10^{-3}	8.37×10^{-2}	1.31×10^{-3}
Death rate of infected cells	δ (day ⁻¹)	0.66	0.67	0.46
Viral load at symptom onset	$V(0)$ (copies/ml)	2.54	5.89	3.05
Quantities derived from estimated parameters				
Within-host basic reproduction number	R_0	4.67	4.66	6.72
Critical inhibition rate	C^*	0.79	0.79	0.85
Length of virus production	L	1.51	1.49	2.17
Length of viral load above detection limit	T_{VL} (days)	29.6	31.9	16.3

[†] Median value


A









B



C





Supplementary Appendix

Modelling SARS-CoV-2 Dynamics: Implications for Therapy

Kwang Su Kim¹, Keisuke Ejima², Yusuke Ito¹, Shoya Iwanami¹, Hirofumi Ohashi³, Yoshiki Koizumi⁴, Yusuke Asai⁴, Shinji Nakaoka^{5,6}, Koichi Watashi^{3,7,8,9,10}, Robin N. Thompson^{11,12*}, and Shingo Iwami^{1,9,10,13*}

¹Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan. ²Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA. ³Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan. ⁴National Center for Global Health and Medicine, Tokyo, Japan. ⁵Faculty of Advanced Life Science, Hokkaido University, Sapporo, Japan. ⁶PRESTO, JST, Saitama, Japan. ⁷Department of Applied Biological Science, Tokyo University of Science, Noda, Japan. ⁸MIRAI, JST, Saitama, Japan. ⁹CREST, JST, Saitama, Japan. ¹⁰Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan. ¹¹Christ Church, University of Oxford, Oxford OX1 1DP, UK. ¹²Mathematical Institute, University of Oxford, Oxford OX2 6GG, UK, Fukuoka, UK. ¹³Science Groove Inc., Fukuoka, Japan.

Table S1. Individual estimated parameters and initial values

Patient ID	γ	β	δ	$V(0)$	L	R_0	C^*	T_{VL}
SAVS-CoV-2 patients: datasets are obtained from throat swabs								
C	4.85	2.08×10^{-4}	1.64	1.66×10^3	0.61	2.96	0.66	7.7
D	4.7	2.42×10^{-5}	1.52	3.71×10^5	0.66	3.09	0.68	10.4
E	3.65	1.51×10^{-5}	1.7	2.11×10^{-5}	0.59	2.15	0.53	13.2
F	4.86	4.15×10^{-5}	1.61	34.9	0.62	3.02	0.67	9.4
H	4.7	5.92×10^{-4}	1.77	6.1×10^3	0.56	2.66	0.62	6.6
I	4.47	8.08×10^{-8}	1.46	1.18	0.68	3.06	0.67	17.4
K	4.7	3.97×10^{-5}	1.58	9.1	0.63	2.97	0.66	9.7
L	3.89	6.55×10^{-6}	1.65	0.14×10^{-2}	0.61	2.36	0.58	13.5
N	4.7	3.97×10^{-5}	1.58	9.1	0.63	2.97	0.66	9.7
O	4.86	1.09×10^{-4}	1.63	26.7	0.61	2.98	0.66	8.4
P	4.7	3.97×10^{-5}	1.58	9.1	0.63	2.97	0.66	9.7
Q	4.63	2.29×10^{-5}	1.60	8.38	0.63	2.89	0.65	10.4
S	4.7	3.97×10^{-5}	1.58	9.1	0.63	2.97	0.66	9.7
T	4.49	5.48×10^{-5}	1.57	2.27	0.64	2.86	0.65	9.7
MERS-CoV severe patients: datasets are obtained from throat swabs								
1	3.57	2.61×10^{-7}	1.16	0.80×10^{-3}	0.86	3.08	0.68	13.7
2	3.7	1.00×10^{-6}	1.44	0.99×10^{-3}	0.69	2.57	0.61	11.0
3	3.82	2.21×10^{-6}	1.57	2.08×10^{-3}	0.64	2.43	0.59	9.6
4	3.00	1.00×10^{-6}	1.48	0.33×10^{-3}	0.68	2.03	0.51	13.2
5	3.69	9.96×10^{-6}	1.43	1.03×10^{-3}	0.70	2.58	0.61	11.0
6	3.64	1.43×10^{-6}	1.54	1.19×10^{-3}	0.65	2.36	0.58	10.6
7	4.09	1.97×10^{-6}	1.19	2.79×10^{-2}	0.84	3.44	0.71	9.9
8	3.38	1.34×10^{-6}	2.3	0.47×10^{-3}	0.43	1.47	0.32	13.6
9	4.2	2.04×10^{-6}	1.58	4.22×10^{-3}	0.63	2.66	0.62	9.0
MERS-CoV mild patients: datasets are obtained from throat swabs								
10	3.35	1.46×10^{-6}	2.63	0.60×10^{-3}	0.38	1.27	0.21	16.3
11	3.36	1.46×10^{-6}	2.46	0.58×10^{-3}	0.41	1.37	0.27	14.6
12	3.7	2.61×10^{-6}	1.97	0.49×10^{-3}	0.51	1.88	0.47	9.8
13	4.19	3.84×10^{-6}	1.98	0.36×10^{-3}	0.51	2.12	0.53	8.1
14	3.36	1.46×10^{-6}	2.53	0.63×10^{-3}	0.40	1.33	0.25	15.2
15	3.36	1.46×10^{-6}	2.46	0.58×10^{-3}	0.41	1.37	0.27	14.6
16	3.52	1.46×10^{-6}	1.76	0.81×10^{-3}	0.57	2.00	0.50	11.0
17	3.47	1.46×10^{-6}	1.89	0.68×10^{-3}	0.53	1.84	0.46	11.3
SAVS-CoV patients: datasets are obtained from nasopharyngeal aspirate								
A	3.05	2.59×10^{-8}	0.70	1.87	1.43	4.36	0.77	23.0
B	3.07	7.67×10^{-8}	0.70	2.28	1.43	4.39	0.77	20.6
C	3.12	2.41×10^{-7}	0.68	3.61	1.47	4.59	0.78	18.7
D	3.14	3.31×10^{-8}	0.52	4.55	1.92	6.04	0.83	26.7
E	3.05	1.51×10^{-7}	0.86	1.83	1.16	3.55	0.72	17.6
F	3.08	1.78×10^{-7}	0.82	2.37	1.22	3.76	0.73	17.6
G	3.06	6.67×10^{-8}	0.90	1.90	1.11	3.40	0.71	18.6
H	3.05	3.41×10^{-8}	0.65	1.82	1.54	4.69	0.79	23.4
I	3.03	2.82×10^{-7}	1.01	1.45	0.99	3.00	0.67	15.6
J	3.12	1.72×10^{-8}	0.51	3.97	1.96	6.12	0.84	28.8
K	3.11	2.62×10^{-8}	0.63	3.23	1.59	4.94	0.80	24.2
L	3.11	1.57×10^{-7}	0.65	3.31	1.54	4.78	0.79	20.0
M	3.13	3.22×10^{-7}	0.63	4.32	1.59	4.97	0.80	18.9

N	3.12	1.58×10^{-8}	0.55	3.80	1.82	5.67	0.82	27.6
MERS-CoV severe patients: datasets are obtained from sputum or tracheal aspirate								
1	3.10	3.26×10^{-8}	0.40	3.14	2.50	7.75	0.87	39.5
2	3.12	3.79×10^{-8}	0.44	3.75	2.27	7.09	0.86	30.4
3	3.08	0.46×10^{-8}	0.47	2.56	2.13	6.55	0.85	33.9
4	3.09	1.16×10^{-8}	0.59	2.69	1.69	5.24	0.81	27.0
5	3.09	1.13×10^{-8}	0.42	2.75	2.38	7.36	0.86	34.7
6	3.10	5.84×10^{-8}	0.53	2.89	1.89	5.85	0.83	25.4
MERS-CoV mild patient: datasets are obtained from sputum or tracheal aspirate								
10	3.16	5.84×10^{-7}	0.65	6.19	1.54	4.86	0.79	18.5
11	3.13	2.60×10^{-6}	0.62	4.85	1.61	5.05	0.80	14.8
12	3.12	4.63×10^{-7}	0.76	3.52	1.32	4.11	0.76	16.3